Recent Updates
Recently added Catalysts
BFRI Positive Sentiment Score: 70/100

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Key Takeaway: Biofrontera Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The event will include a webcast presentation at 1:15 p.m. ET and virtual one-on-one meetings with investors. This participation underscores Biofrontera's focus on investor relations and its commitment to discussing its dermatological products.

Market Sentiment Analysis

POSITIVE FACTORS

  • Biofrontera is actively engaging with investors through a virtual conference.
  • The company showcases its commitment to transparency and communication.
  • Participation in the conference highlights Biofrontera's growth and development in dermatology.

Full Press Release Details

Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) --Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

Company Webcast

The webcast presentation will take place at 1:15 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page athttps://lythampartners.com/fall2025/or directly athttps://app.webinar.net/wWqPp4Yr0kD. The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at1x1@lythampartners.comor register for the event athttps://lythampartners.com/fall2025invreg/.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz®with the RhodoLED®lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visitwww.biofrontera-us.comand follow Biofrontera onLinkedInandX.
Investor Relations Contact

Frequently Asked Questions

When is the Lytham Partners Fall 2025 Investor Conference?

The conference will take place on September 30, 2025.

How can I access the Biofrontera webcast?

The webcast can be accessed via the conference home page or directly through a provided link.

What will Biofrontera present at the conference?

Biofrontera will present information about its dermatological products and engage in investor discussions.

How can investors arrange one-on-one meetings?

Investors can arrange meetings by contacting Lytham Partners or registering for the event.

Last updated: Sep 26, 2025